Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Prostate Cancer

  Free Subscription


14.01.2019

1 Anticancer Res
4 BMC Cancer
2 BMC Urol
1 Cancer
1 Cancer Res
1 Eur Radiol
7 Eur Urol
1 Genes Chromosomes Cancer
2 Int J Cancer
2 Int J Radiat Oncol Biol Phys
1 J Cell Physiol
1 J Clin Oncol
1 Magn Reson Imaging
1 Nat Rev Urol
1 Oncology
1 PLoS One
1 Proc Natl Acad Sci U S A
6 Prostate
2 Urol Int
5 Urology


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Anticancer Res

  1. LI JR, Wang SS, Lin CH, DE Groat WC, et al
    Positive Association of Male Overactive Bladder Symptoms and Androgen Deprivation: A Nationwide Population-based Cohort Study.
    Anticancer Res. 2019;39:305-311.
    PubMed     Text format     Abstract available


    BMC Cancer

  2. CALAIS J, Czernin J, Fendler WP, Elashoff D, et al
    Randomized prospective phase III trial of (68)Ga-PSMA-11 PET/CT molecular imaging for prostate cancer salvage radiotherapy planning [PSMA-SRT].
    BMC Cancer. 2019;19:18.
    PubMed     Text format     Abstract available

  3. QIU X, Wang W, Li B, Cheng B, et al
    Targeting Ezh2 could overcome docetaxel resistance in prostate cancer cells.
    BMC Cancer. 2019;19:27.
    PubMed     Text format     Abstract available

  4. HEIDENREICH A, Gillessen S, Heinrich D, Keizman D, et al
    Radium-223 in asymptomatic patients with castration-resistant prostate cancer and bone metastases treated in an international early access program.
    BMC Cancer. 2019;19:12.
    PubMed     Text format     Abstract available

  5. ALIBHAI SMH, Santa Mina D, Ritvo P, Tomlinson G, et al
    A phase II randomized controlled trial of three exercise delivery methods in men with prostate cancer on androgen deprivation therapy.
    BMC Cancer. 2019;19:2.
    PubMed     Text format     Abstract available


    BMC Urol

  6. JOHNSTON WL, Catton CN, Swallow CJ
    Unbiased data mining identifies cell cycle transcripts that predict non-indolent Gleason score 7 prostate cancer.
    BMC Urol. 2019;19:4.
    PubMed     Text format     Abstract available

  7. ANDIC F, Izol V, Gokcay S, Arslantas HS, et al
    Definitive external-beam radiotherapy versus radical prostatectomy in clinically localized high-risk prostate cancer: a retrospective study.
    BMC Urol. 2019;19:3.
    PubMed     Text format     Abstract available


    Cancer

  8. SONPAVDE G, Agarwal N, Pond GR, Nagy RJ, et al
    Circulating tumor DNA alterations in patients with metastatic castration-resistant prostate cancer.
    Cancer. 2019 Jan 8. doi: 10.1002/cncr.31959.
    PubMed     Text format     Abstract available


    Cancer Res

  9. VUMMIDI GIRIDHAR P, Williams K, VonHandorf AP, Deford PL, et al
    Constant Degradation of the Androgen Receptor by MDM2 Conserves Prostate Cancer Stem Cell Integrity.
    Cancer Res. 2019 Jan 9. pii: 0008-5472.CAN-18-1753.
    PubMed     Text format     Abstract available


    Eur Radiol

  10. DOMACHEVSKY L, Goldberg N, Bernstine H, Nidam M, et al
    Quantitative characterisation of clinically significant intra-prostatic cancer by prostate-specific membrane antigen (PSMA) expression and cell density on PSMA-11.
    Eur Radiol. 2018;28:5275-5283.
    PubMed     Text format     Abstract available


    Eur Urol

  11. HERLEMANN A, Cowan JE, Carroll PR, Cooperberg MR, et al
    Community-based Outcomes of Open versus Robot-assisted Radical Prostatectomy.
    Eur Urol. 2018;73:215-223.
    PubMed     Text format     Abstract available

  12. BRZEZNIAK C, Oronsky B, Aggarwal R
    A Complete Metabolic Response of Metastatic Castration-resistant Neuroendocrine Carcinoma of the Prostate After Treatment with RRx-001 and Reintroduced Platinum Doublets.
    Eur Urol. 2018;73:306-307.
    PubMed     Text format    

  13. HEIDEGGER I, Pichler R
    Re: Peter K.-F. Chiu, Chi-Fai Ng, Axel Semjonow, et al. A Multicentre Evaluation of the Role of the Prostate Health Index (PHI) in Regions with Differing Prevalence of Prostate Cancer: Adjustment of PHI Reference Ranges is Needed for European and Asia
    Eur Urol. 2019 Jan 4. pii: S0302-2838(18)31049.
    PubMed     Text format    

  14. KRETSCHMER A, Gleave ME
    Re: Radiotherapy to the Primary Tumour for Newly Diagnosed, Metastatic Prostate Cancer (STAMPEDE).
    Eur Urol. 2019 Jan 4. pii: S0302-2838(18)31043.
    PubMed     Text format    

  15. VIS AN, Boeve LMS
    Reply to Fabiana Gregucci and Alba Fiorentino's Letter to the Editor re: Liselotte M.S. Boeve, Maarten C.C.M. Hulshof, Andre N. Vis, et al. Effect on Survival of Androgen Deprivation Therapy Alone Compared to Androgen Deprivation Therapy Combined with
    Eur Urol. 2019 Jan 4. pii: S0302-2838(18)31029.
    PubMed     Text format    

  16. CIRIACO P, Briganti A, Bernabei A, Gandaglia G, et al
    Safety and Early Oncologic Outcomes of Lung Resection in Patients with Isolated Pulmonary Recurrent Prostate Cancer: A Single-center Experience.
    Eur Urol. 2019 Jan 4. pii: S0302-2838(18)31035.
    PubMed     Text format     Abstract available

  17. MURPHY DG, Azad AA, Sandhu S, Violet J, et al
    Prostate-specific Membrane Antigen Across the Spectrum of Prostate Cancer: Detection, Surgery, and Theranostics.
    Eur Urol. 2019 Jan 4. pii: S0302-2838(18)31047.
    PubMed     Text format    


    Genes Chromosomes Cancer

  18. KLUTH M, Abdelaziz Z, Ozden C, Hussein K, et al
    5q21 deletion is often heterogeneous in prostate cancer.
    Genes Chromosomes Cancer. 2019 Jan 9. doi: 10.1002/gcc.22730.
    PubMed     Text format     Abstract available


    Int J Cancer

  19. LIU Q, Wang G, Li Q, Jiang W, et al
    Polycomb Group Proteins EZH2 and EED Directly Regulate Androgen Receptor in Advanced Prostate Cancer.
    Int J Cancer. 2019 Jan 10. doi: 10.1002/ijc.32118.
    PubMed     Text format     Abstract available

  20. SAMPSON N, Brunner E, Weber A, Puhr M, et al
    Inhibition of Nox4-dependent ROS signaling attenuates prostate fibroblast activation and abrogates stromal-mediated protumorigenic interactions.
    Int J Cancer. 2018;143:383-395.
    PubMed     Text format     Abstract available


    Int J Radiat Oncol Biol Phys

  21. ZELEFSKY MJ, Kollmeier M, McBride S, Varghese M, et al
    5-Year Outcomes of a Phase I Dose Escalation Study Using Stereotactic Body Radiosurgery for Patients with Low and Intermediate Risk Prostate Cancer.
    Int J Radiat Oncol Biol Phys. 2019 Jan 3. pii: S0360-3016(18)34227.
    PubMed     Text format     Abstract available

  22. GLICKSMAN R, Sanmamed N, Thoms J, Zlotta AR, et al
    A phase I pilot study of pre-operative radiotherapy for prostate cancer: Long-term toxicity and oncologic outcomes.
    Int J Radiat Oncol Biol Phys. 2019 Jan 6. pii: S0360-3016(19)30001.
    PubMed     Text format     Abstract available


    J Cell Physiol

  23. LIU DC, Song LL, Liang Q, Hao L, et al
    Long noncoding RNA LEF1-AS1 silencing suppresses the initiation and development of prostate cancer by acting as a molecular sponge of miR-330-5p via LEF1 repression.
    J Cell Physiol. 2019 Jan 5. doi: 10.1002/jcp.27893.
    PubMed     Text format     Abstract available


    J Clin Oncol

  24. CASTRO E, Romero-Laorden N, Del Pozo A, Lozano R, et al
    PROREPAIR-B: A Prospective Cohort Study of the Impact of Germline DNA Repair Mutations on the Outcomes of Patients With Metastatic Castration-Resistant Prostate Cancer.
    J Clin Oncol. 2019 Jan 9:JCO1800358. doi: 10.1200/JCO.18.00358.
    PubMed     Text format     Abstract available


    Magn Reson Imaging

  25. OGURA A, Maeda F, Yahata S, Koyama D, et al
    Slow component apparent diffusion coefficient for prostate cancer: Comparison and correlation with pharmacokinetic evaluation from dynamic contrast-enhanced MR imaging.
    Magn Reson Imaging. 2019 Jan 7. pii: S0730-725X(18)30524.
    PubMed     Text format     Abstract available


    Nat Rev Urol

  26. BRADLEY CA
    Evolutionary and clinical trajectories of early-onset prostate cancer.
    Nat Rev Urol. 2019 Jan 4. pii: 10.1038/s41585-019-0144.
    PubMed     Text format    


    Oncology

  27. FENG LR, Fuss T, Dickinson K, Ross A, et al
    Co-Occurring Symptoms Contribute to Persistent Fatigue in Prostate Cancer.
    Oncology. 2019 Jan 9:1-9. doi: 10.1159/000494620.
    PubMed     Text format     Abstract available


    PLoS One

  28. FONSECA-ALVES CE, Kobayashi PE, Rivera Calderon LG, Felisbino SL, et al
    Immunohistochemical panel to characterize canine prostate carcinomas according to aberrant p63 expression.
    PLoS One. 2018;13:e0199173.
    PubMed     Text format     Abstract available


    Proc Natl Acad Sci U S A

  29. LORENZO G, Hughes TJR, Dominguez-Frojan P, Reali A, et al
    Computer simulations suggest that prostate enlargement due to benign prostatic hyperplasia mechanically impedes prostate cancer growth.
    Proc Natl Acad Sci U S A. 2019 Jan 7. pii: 1815735116.
    PubMed     Text format     Abstract available


    Prostate

  30. HATANAKA Y, de Velasco MA, Oki T, Shimizu N, et al
    HOXA10 expression profiling in prostate cancer.
    Prostate. 2019 Jan 6. doi: 10.1002/pros.23761.
    PubMed     Text format     Abstract available

  31. PAPANICOLAU-SENGOS A, Yang Y, Pabla S, Lenzo FL, et al
    Identification of targets for prostate cancer immunotherapy.
    Prostate. 2019 Jan 6. doi: 10.1002/pros.23756.
    PubMed     Text format     Abstract available

  32. FAN L, Yang Y, Chi C, Ma X, et al
    Neuroendocrine differentiation markers guide treatment sequence selection in metastatic castration-resistant prostate cancer.
    Prostate. 2019 Jan 6. doi: 10.1002/pros.23762.
    PubMed     Text format     Abstract available

  33. LIU Y, Wu X, Jiang H
    Combined maternal and post-weaning high fat diet inhibits male offspring's prostate cancer tumorigenesis in transgenic adenocarcinoma of mouse prostate model.
    Prostate. 2019 Jan 6. doi: 10.1002/pros.23760.
    PubMed     Text format     Abstract available

  34. ZHAO M, Qi M, Li X, Hu J, et al
    CUL4B/miR-33b/C-MYC axis promotes prostate cancer progression.
    Prostate. 2019 Jan 4. doi: 10.1002/pros.23754.
    PubMed     Text format     Abstract available

  35. BROADFIELD LA, Marcinko K, Tsakiridis E, Zacharidis PG, et al
    Salicylate enhances the response of prostate cancer to radiotherapy.
    Prostate. 2019 Jan 4. doi: 10.1002/pros.23755.
    PubMed     Text format     Abstract available


    Urol Int

  36. XIANG C, Liu X, Chen S, Wang P, et al
    Prediction of Biochemical Recurrence Following Radiotherapy among Patients with Persistent PSA after Radical Prostatectomy: A Single-Center Experience.
    Urol Int. 2018;101:47-55.
    PubMed     Text format     Abstract available

  37. HASHIMOTO M, Matsumura N, Ohzeki T, Hongo S, et al
    The Change in Neutrophil Lymphocyte Ratio from the First to the Last Repeat Prostate Biopsy Proposed as a Marker of Carcinogenesis.
    Urol Int. 2018;101:74-79.
    PubMed     Text format     Abstract available


    Urology

  38. AGARWAL DK, Miest TS, Granberg CF, Frank I, et al
    Pediatric Robotic Prostatectomy and Pelvic Lymphadenectomy for Embryonal Rhabdomyosarcoma.
    Urology. 2018;119:143-145.
    PubMed     Text format     Abstract available

  39. KAOUK JH, Garisto J, Sagalovich D, Dagenais J, et al
    Robotic Single-port Partial Prostatectomy for Anterior Tumors: Transvesical Approach.
    Urology. 2018;118:242.
    PubMed     Text format     Abstract available

  40. ALPERT PF
    New Evidence for the Benefit of Prostate-specific Antigen Screening: Data From 400,887 Kaiser Permanente Patients.
    Urology. 2018;118:119-126.
    PubMed     Text format     Abstract available

  41. EGGENER S, Karsh LI, Richardson T, Shindel AW, et al
    A 17-gene Panel for Prediction of Adverse Prostate Cancer Pathologic Features: Prospective Clinical Validation and Utility.
    Urology. 2019 Jan 3. pii: S0090-4295(19)30001.
    PubMed     Text format     Abstract available

  42. MONDA SM, Vetter JM, Andriole GL, Fowler KJ, et al
    Cognitive Versus Software Fusion for MRI-targeted Biopsy: Experience Before and After Implementation of Fusion.
    Urology. 2018;119:115-120.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: